Treatment Effectiveness of Shifting from Risperidone Long-acting Injectable to First-generation Long-acting Injectable Antipsychotics in Patients with Schizophrenia

Ching-Yin Chang ； Hung-Yu Chan

《台灣精神醫學》 33卷3期 (2019/09) Pp. 135-141

https://doi.org/10.4103/TPSY.TPSY_27_19

摘要

Objectives: Most studies of long-acting injectable antipsychotic (LAI) drugs have been focused on the efficacy of second-generation antipsychotic (SGA) LAIs through observation of the various outcomes of shifting from first-generation antipsychotic (FGA) LAIs to SGA LAIs. Rare studies have assessed the effectiveness of shifting from SGA LAIs to FGA LAIs. In this study, we intended to investigate the effectiveness of shifting from risperidone LAI to FGA LAIs in patients with schizophrenia. Methods: We included patients with schizophrenia and with the ownership of catastrophic illness card in the study. All the study patients had received risperidone LAI at least two months with a minimal dose of 50 mg per month. The case group included the patients who had been shifting from risperidone LAI to FGA LAIs (fluphenazine, haloperidol, or flupentixol). The control group included the patients who were continuously maintaining on risperidone LAI. The primary outcome was the time to hospitalization. The secondary outcomes were the side effects requiring to receive the use of concomitant anticholinergics, propranolol, and benzodiazepines. Results: We had 15 patients in the case group and 98 patients in the control group. The primary outcomes showed no significant between-group difference in the time to hospitalization (hazard ratio = 3.676, 95% confidence interval = 0.833 - 16.222). The secondary outcomes also showed no significant differences between the case and control groups. Conclusion: This study showed no significant differences in the treatment effectiveness and side effects between FGA LAIs and risperidone LAI. The results are compatible with those from a previous LAI study from the National Institute of Mental Health of the United States. But the relatively small effect with inadequate statistical power is the major study limitation, which may produce no significant differences in side effects. We suggest that further large-sample study is needed to confirm the results of this study.

關鍵字

extrapyramidal symptoms ； nonadherence ； side effects of antipsychotic drugs ； time to hospitalization

參考文獻

Chan HY, Pan YJ, Chen JJ, et al.: Time to discontinuation of second-generation antipsychotics versus haloperidol and sulpiride in people with schizophrenia: a naturalistic, comparative study. J Clin Psychopharmacol 2017; 37: 13-20.

Valenstein M, Blow FC, Copeland LA, et al.: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-64.

Keith SJ, Kane JM: Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003; 64: 1308-15.

Weiden PJ, Kozma C, Grogg A, et al.: Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-91.

Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.